Samsung Biologics stock (KR7207940008): CDMO leader navigates South Korea biotech landscape

Samsung Biologics, South Korea's largest contract manufacturing organization, combines rapid revenue growth with strong profitability. The biopharmaceutical company serves global clients across biosimilars and CDMO services.

Samsung Biologics Co Ltd operates as South Korea's leading contract development and manufacturing organization (CDMO), serving biopharmaceutical clients worldwide. The company generates the majority of its revenue from CDMO services, which include biopharmaceutical contract manufacturing, cell line development, and process development. A secondary segment focuses on developing and commercializing biosimilars across therapeutic areas including autoimmune, oncology, ophthalmology, and hematology.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Samsung Biologics Co Ltd
• Sector/industry: Biotechnology / Biopharmaceutical Services
• Headquarters/country: Incheon, South Korea
• Core markets: Global CDMO and biosimilar development
• Key revenue drivers: Contract manufacturing services (CDMO segment), biosimilar development and commercialization
• Home exchange/listing venue: Korea Exchange (KRX), ticker 207940
• Trading currency: South Korean Won (KRW)
• Employees: Approximately 5,273

Samsung Biologics: core business model

Samsung Biologics operates two primary business segments. The Contract Development and Manufacturing Organization (CDMO) segment provides comprehensive biopharmaceutical manufacturing services, including cell line development, process optimization, and large-scale production. This segment accounts for the majority of company revenue and serves multinational pharmaceutical and biotechnology clients seeking manufacturing capacity and expertise. The company operates state-of-the-art facilities in Incheon, South Korea, positioning it as a critical infrastructure provider for the global biopharmaceutical supply chain.

The Biopharmaceutical Development and Commercialization segment focuses on developing proprietary biosimilars—biologically derived drugs that replicate approved reference biologics. Samsung Biologics targets therapeutic areas with significant market opportunity, including autoimmune diseases, oncology, ophthalmology, and hematology. This dual-segment approach allows the company to generate revenue from contract services while building a pipeline of proprietary products with higher margin potential.

Main revenue and product drivers for Samsung Biologics

The CDMO segment remains the primary revenue engine, driven by global demand for biopharmaceutical manufacturing capacity. As biologic drug development accelerates worldwide, contract manufacturers like Samsung Biologics benefit from pharmaceutical companies outsourcing production to specialized facilities. The company's large-scale manufacturing platform and technical expertise position it to capture market share in this growing sector. Revenue from CDMO services reflects both volume growth and pricing dynamics in the contract manufacturing market.

The biosimilar development segment contributes to long-term growth potential. Biosimilars represent a significant opportunity as patents on blockbuster biologic drugs expire, creating demand for lower-cost alternatives. Samsung Biologics' pipeline includes candidates across multiple therapeutic areas, with commercialization timelines extending over several years. Success in biosimilar development could diversify revenue streams and improve overall profitability as these products reach market.

Why Samsung Biologics matters for US investors

Samsung Biologics serves as a critical infrastructure provider for the global biopharmaceutical industry, including major US pharmaceutical and biotechnology companies. US investors with exposure to biopharmaceutical manufacturing trends benefit from understanding Samsung Biologics' role in the supply chain. The company's CDMO services support drug development and production for US-listed biopharmaceutical firms, making it relevant to investors tracking the broader biotech ecosystem and manufacturing capacity dynamics.

Conclusion

Samsung Biologics operates as South Korea's leading contract manufacturing organization and biosimilar developer, combining rapid revenue growth with strong profitability. The company's dual-segment model—CDMO services and proprietary biosimilar development—positions it to benefit from structural trends in biopharmaceutical outsourcing and the biosimilar market expansion. US investors tracking global biopharmaceutical manufacturing capacity and supply chain dynamics may find Samsung Biologics relevant to their investment thesis, though the company's South Korean listing and won-denominated trading introduce currency and market-specific considerations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.